{
    "clinical_study": {
        "@rank": "156471", 
        "arm_group": {
            "arm_group_label": "DynaSense sensor", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The study is designed to test the DynaSense system, which is a patient movement and\n      orientation monitoring system. The study is intended to determine that:\n\n        -  the DynaSense system identifies patients that are not turning adequately on their own\n           and therefore require caregiver-assisted turns.\n\n        -  the DynaSense system identifies patients that are turning adequately on their own and\n           therefore do not require a caregiver-assisted turn.\n\n        -  the DynaSense system helps ensure compliance with an institution's established patient\n           turning protocol."
        }, 
        "brief_title": "A Pilot Study to Assess the DynaSense System", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "condition": "Pressure Ulcers", 
        "condition_browse": {
            "mesh_term": [
                "Pressure Ulcer", 
                "Ulcer"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult male or female 18 to 110 years of age;\n\n          -  Inpatient currently on the unit and expected to remain for at least 12 hours;\n\n          -  Able and willing to comply with the study procedures;\n\n          -  Subject (or his/her agent) is able to read, understand, and provide Informed Consent\n             in the English language.\n\n        Exclusion Criteria:\n\n          -  Subject is a female subject under the age of 60 who is pregnant, planning on becoming\n             pregnant, or is currently breastfeeding.\n\n               1. Any woman under the age of 60, must have a negative urine pregnancy test prior\n                  to being enrolled in the study; OR\n\n               2. Be postmenopausal for at least 2 years, OR\n\n               3. have had a bilateral tubal ligations, OR\n\n               4. have had a bilateral oophorectomy, OR\n\n               5. have had a hysterectomy.\n\n          -  Subjects with a known tape allergy or sensitivity to EKG leads or similar types of\n             adhesives used in common medical products.\n\n          -  Subjects who cannot have the patient sensor applied on the surface of the patient's\n             anterior torso.\n\n          -  Subjects who have a pacemaker or implantable cardiovascular-defibrillator (ICD).\n\n          -  Subjects with dementia, Alzheimer's disease or other mental disabilities and\n             incapacitation that would prevent the subject from providing written informed\n             consent. If the subject is unable to provide informed consent due to mental\n             incapacity, then the subject's Durable Power of Attorney may provide informed consent\n             and sign the informed consent on behalf of the subject.\n\n          -  Subjects who refuse to have an area of hair on their chest be clipped or shaved, if\n             needed for patient sensor adhesion.\n\n          -  Subjects, who in the opinion of the Principal Investigator, are at increased risk by\n             participating in the clinical study.\n\n          -  Subjects who have participated in another clinical study within the past 30 days or\n             are currently participating in another clinical study at the time of screening."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02005692", 
            "org_study_id": "CM-002"
        }, 
        "intervention": {
            "arm_group_label": "DynaSense sensor", 
            "intervention_name": "DynaSense sensor", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "pressure ulcers", 
            "bed sores", 
            "patient turn protocol", 
            "patient movement", 
            "patient monitoring"
        ], 
        "lastchanged_date": "May 19, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Mountain View", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94040"
                }, 
                "name": "El Camino Hospital"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Pilot Study to Assess the DynaSense System", 
        "overall_official": {
            "affiliation": "El Camino Hospital", 
            "last_name": "Michelle Pezzani, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "The safety primary endpoint is to assess safety by documenting the number, type, and severity of side effects and adverse events.", 
                "measure": "Safety Primary Endpoint", 
                "safety_issue": "Yes", 
                "time_frame": "Subjects will be followed for the length of hospital stay which is expected to average 5 days, or until resolution of ADE."
            }, 
            {
                "description": "The primary clinical efficacy endpoint is to measure the rate of compliance with prescribed patient turning protocols by using the DynaSense system.", 
                "measure": "Efficacy Primary Endpoint", 
                "safety_issue": "No", 
                "time_frame": "Subjects will be followed for the length of hospital stay which is expected to average 5 days."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02005692"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The secondary efficacy clinical endpoint is to measure the severity of non-compliance with turning protocols, which is a measure which reflects the average amount of time that turns are past due.", 
            "measure": "Secondary Efficacy Clinical Endpoint", 
            "safety_issue": "No", 
            "time_frame": "Subjects will be followed for the length of hospital stay which is expected to average 5 days."
        }, 
        "source": "Leaf Healthcare, Inc.", 
        "sponsors": {
            "collaborator": {
                "agency": "Centauri Medical, Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Leaf Healthcare, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}